晚期非小细胞肺癌一线免疫联合治疗的疗效与安全性:系统评价与网络荟萃分析
该研究通过系统评价和贝叶斯网络荟萃分析16项随机对照试验共8278例晚期NSCLC患者,比较10种一线免疫联合方案。结果显示抗PD-1联合方案生存获益可能优于抗PD-L1联合方案且安全性相当;PD-L1阴性患者中纳武利尤单抗+伊匹木单抗+化疗OS最佳,PD-L1阳性患者中帕博利珠单抗+化疗OS最佳。
要点
- 抗PD-1联合方案较抗PD-L1联合方案可能带来更高生存获益且安全性相当。
- PD-L1<1%患者中纳武利尤单抗+伊匹木单抗+化疗OS最佳。
- PD-L1≥1%患者中帕博利珠单抗+化疗OS最佳。
核心结论
- 抗PD-1联合方案较抗PD-L1联合方案可能带来更高生存获益且安全性相当。
- 帕博利珠单抗+化疗和纳武利尤单抗+伊匹木单抗+化疗似乎分别是PD-L1阳性和阴性晚期NSCLC患者的优越一线免疫联合方案。
研究设计与样本
- 系统评价与贝叶斯网络荟萃分析,检索PubMed、EMBASE、Cochrane Library、ClinicalTrials.gov及主要国际会议。
- 纳入16项随机对照试验共8278例晚期NSCLC患者,涉及10种一线免疫联合方案。
主要发现
- 在未筛选PD-L1的患者中,帕博利珠单抗+化疗与信迪利单抗+化疗的OS获益相当(HR=0.96,95%CI:0.72-1.29)。
- 阿替利珠单抗+贝伐珠单抗+化疗似乎提供最佳PFS(HR=0.45,95%CI:0.36-0.55)和最佳ORR(OR=0.23,95%CI:0.12-0.42)。
- PD-L1<1%患者中纳武利尤单抗+伊匹木单抗+化疗与最佳OS相关,PD-L1≥1%患者中帕博利珠单抗+化疗与最佳OS相关。
- 与其他免疫联合化疗相比,帕博利珠单抗和信迪利单抗的≥3级不良事件相对较少。
临床怎么用
- PD-L1阳性晚期NSCLC一线可优先考虑帕博利珠单抗+化疗。
- PD-L1阴性晚期NSCLC一线可考虑纳武利尤单抗+伊匹木单抗+化疗。
- 选择阿替利珠单抗+贝伐珠单抗+化疗时需注意联合抗血管生成和化疗增加的毒性。
局限性
- 原文未明确报告纳入研究的偏倚风险或异质性评估结果。
- 原文未报告网络荟萃分析中不一致性检验的具体结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A series of randomized controlled trials have investigated different first-line immunotherapy combinations, but the optimal combination strategy is yet to be established. METHODS: We performed a systematic review and Bayesian network meta-analysis by retrieving relevant literature from PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, and major international conferences. We included published and gray sources of randomized clinical trials comparing immunotherapy combinations with other treatments as first-line treatments for patients with advanced NSCLC. This study was registered in the Prospective Register of Systematic Reviews (CRD42020210501) to ensure transparency. RESULTS: We analyzed a total of 16 studies involving 8278 patients and including 10 immunotherapy combinations. For patients without programmed death-ligand 1 (PD-L1) selection, pembrolizumab plus chemotherapy was found to be comparable with sintilimab plus chemotherapy in providing the best overall survival (OS) benefit (hazard ratio = 0.96, 95% confidence interval [CI]: 0.72-1.29). Furthermore, atezolizumab plus bevacizumab plus chemotherapy seemed to provide the best progression-free survival (hazard ratio = 0.45, 95% CI: 0.36-0.55) and the best objective response rate (OR = 0.23, 95% CI: 0.12-0.42). Subgroup analysis by PD-L1 suggested that nivolumab plus ipilimumab plus chemotherapy was associated with the best OS in patients with PD-L1 less than 1% and that pembrolizumab plus chemotherapy was associated with the best OS in patients with PD-L1 greater than or equal to 1%. Pembrolizumab and sintilimab were associated with relatively fewer grade greater than or equal to 3 adverse events when compared with other immunotherapies combined with chemotherapy. CONCLUSIONS: Our results suggest that antiprogrammed death-1 combinations are associated with potentially higher survival outcomes than anti-PD-L1 combinations with comparable safety profiles. Moreover, pem-chemo and nivo-ipi-chemo seem to be superior first-line immunotherapy combinations for patients with advanced NSCLC with positive and negative PD-L1 expression, respectively. Although atezo-beva-chemo treatment provided the best progression-free survival and objective response rate, the addition of chemotherapy to immunotherapy would increase the toxicity, especially when antiangiogenesis drugs are simultaneously added.
引用
- Liu L, Bai H, Wang C, et al. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. J Thorac Oncol. 2021. PMID: 33839365. doi:10.1016/j.jtho.2021.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。